Cargando…

The impact of retinal fluid tolerance on the outcomes of neovascular age-related macular degeneration treated using aflibercept: A real-world study

This study investigated the impact of retinal fluid tolerance on retinal thickness and visual acuity in patients with neovascular age-related macular degeneration after 18 months of treatment using intravitreal aflibercept. This retrospective study was based on the medical records of 90 eyes present...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeng, Yu-Ting, Lai, Tso-Ting, Lin, Chao-Wen, Chen, Ta-Ching, Hsieh, Yi-Ting, Lin, Chang-Ping, Ho, Tzyy-Chang, Yang, Chung-May, Yang, Chang-Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9333245/
https://www.ncbi.nlm.nih.gov/pubmed/35900984
http://dx.doi.org/10.1371/journal.pone.0271999
_version_ 1784758830554415104
author Jeng, Yu-Ting
Lai, Tso-Ting
Lin, Chao-Wen
Chen, Ta-Ching
Hsieh, Yi-Ting
Lin, Chang-Ping
Ho, Tzyy-Chang
Yang, Chung-May
Yang, Chang-Hao
author_facet Jeng, Yu-Ting
Lai, Tso-Ting
Lin, Chao-Wen
Chen, Ta-Ching
Hsieh, Yi-Ting
Lin, Chang-Ping
Ho, Tzyy-Chang
Yang, Chung-May
Yang, Chang-Hao
author_sort Jeng, Yu-Ting
collection PubMed
description This study investigated the impact of retinal fluid tolerance on retinal thickness and visual acuity in patients with neovascular age-related macular degeneration after 18 months of treatment using intravitreal aflibercept. This retrospective study was based on the medical records of 90 eyes presenting persistent or recurrent retinal fluid retention after 3 months of aflibercept loading injections. We defined the fluid tolerance ratio as the sum of fluid-tolerance duration divided by the total duration of retinal fluid observed throughout the follow-up period. Eyes were categorized into strict, intermediate, and relaxed group based on their fluid tolerance ratio (= 0, <30%, > = 30%, respectively). The mean total follow-up time was 556 days. The relaxed group required fewer injections than the strict group (4.92 vs 7.50 injections, P < 0.01) and presented a similar reduction in retinal thickness (-57.50 vs -71.65 μm, P = 0.83). Nonetheless, the two groups were similar in terms of final visual acuity (logarithm of the minimum angle of resolution 0.72 vs 0.70, P = 0.95) and visual gains (4.21 vs -1.12 letters, P = 0.56). These results indicate that in the setting of limited medical resources, a fluid-tolerant approach provides comparable gains in visual acuity. Reducing the number of injections may also improve adherence to therapy.
format Online
Article
Text
id pubmed-9333245
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-93332452022-07-29 The impact of retinal fluid tolerance on the outcomes of neovascular age-related macular degeneration treated using aflibercept: A real-world study Jeng, Yu-Ting Lai, Tso-Ting Lin, Chao-Wen Chen, Ta-Ching Hsieh, Yi-Ting Lin, Chang-Ping Ho, Tzyy-Chang Yang, Chung-May Yang, Chang-Hao PLoS One Research Article This study investigated the impact of retinal fluid tolerance on retinal thickness and visual acuity in patients with neovascular age-related macular degeneration after 18 months of treatment using intravitreal aflibercept. This retrospective study was based on the medical records of 90 eyes presenting persistent or recurrent retinal fluid retention after 3 months of aflibercept loading injections. We defined the fluid tolerance ratio as the sum of fluid-tolerance duration divided by the total duration of retinal fluid observed throughout the follow-up period. Eyes were categorized into strict, intermediate, and relaxed group based on their fluid tolerance ratio (= 0, <30%, > = 30%, respectively). The mean total follow-up time was 556 days. The relaxed group required fewer injections than the strict group (4.92 vs 7.50 injections, P < 0.01) and presented a similar reduction in retinal thickness (-57.50 vs -71.65 μm, P = 0.83). Nonetheless, the two groups were similar in terms of final visual acuity (logarithm of the minimum angle of resolution 0.72 vs 0.70, P = 0.95) and visual gains (4.21 vs -1.12 letters, P = 0.56). These results indicate that in the setting of limited medical resources, a fluid-tolerant approach provides comparable gains in visual acuity. Reducing the number of injections may also improve adherence to therapy. Public Library of Science 2022-07-28 /pmc/articles/PMC9333245/ /pubmed/35900984 http://dx.doi.org/10.1371/journal.pone.0271999 Text en © 2022 Jeng et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Jeng, Yu-Ting
Lai, Tso-Ting
Lin, Chao-Wen
Chen, Ta-Ching
Hsieh, Yi-Ting
Lin, Chang-Ping
Ho, Tzyy-Chang
Yang, Chung-May
Yang, Chang-Hao
The impact of retinal fluid tolerance on the outcomes of neovascular age-related macular degeneration treated using aflibercept: A real-world study
title The impact of retinal fluid tolerance on the outcomes of neovascular age-related macular degeneration treated using aflibercept: A real-world study
title_full The impact of retinal fluid tolerance on the outcomes of neovascular age-related macular degeneration treated using aflibercept: A real-world study
title_fullStr The impact of retinal fluid tolerance on the outcomes of neovascular age-related macular degeneration treated using aflibercept: A real-world study
title_full_unstemmed The impact of retinal fluid tolerance on the outcomes of neovascular age-related macular degeneration treated using aflibercept: A real-world study
title_short The impact of retinal fluid tolerance on the outcomes of neovascular age-related macular degeneration treated using aflibercept: A real-world study
title_sort impact of retinal fluid tolerance on the outcomes of neovascular age-related macular degeneration treated using aflibercept: a real-world study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9333245/
https://www.ncbi.nlm.nih.gov/pubmed/35900984
http://dx.doi.org/10.1371/journal.pone.0271999
work_keys_str_mv AT jengyuting theimpactofretinalfluidtoleranceontheoutcomesofneovascularagerelatedmaculardegenerationtreatedusingafliberceptarealworldstudy
AT laitsoting theimpactofretinalfluidtoleranceontheoutcomesofneovascularagerelatedmaculardegenerationtreatedusingafliberceptarealworldstudy
AT linchaowen theimpactofretinalfluidtoleranceontheoutcomesofneovascularagerelatedmaculardegenerationtreatedusingafliberceptarealworldstudy
AT chentaching theimpactofretinalfluidtoleranceontheoutcomesofneovascularagerelatedmaculardegenerationtreatedusingafliberceptarealworldstudy
AT hsiehyiting theimpactofretinalfluidtoleranceontheoutcomesofneovascularagerelatedmaculardegenerationtreatedusingafliberceptarealworldstudy
AT linchangping theimpactofretinalfluidtoleranceontheoutcomesofneovascularagerelatedmaculardegenerationtreatedusingafliberceptarealworldstudy
AT hotzyychang theimpactofretinalfluidtoleranceontheoutcomesofneovascularagerelatedmaculardegenerationtreatedusingafliberceptarealworldstudy
AT yangchungmay theimpactofretinalfluidtoleranceontheoutcomesofneovascularagerelatedmaculardegenerationtreatedusingafliberceptarealworldstudy
AT yangchanghao theimpactofretinalfluidtoleranceontheoutcomesofneovascularagerelatedmaculardegenerationtreatedusingafliberceptarealworldstudy
AT jengyuting impactofretinalfluidtoleranceontheoutcomesofneovascularagerelatedmaculardegenerationtreatedusingafliberceptarealworldstudy
AT laitsoting impactofretinalfluidtoleranceontheoutcomesofneovascularagerelatedmaculardegenerationtreatedusingafliberceptarealworldstudy
AT linchaowen impactofretinalfluidtoleranceontheoutcomesofneovascularagerelatedmaculardegenerationtreatedusingafliberceptarealworldstudy
AT chentaching impactofretinalfluidtoleranceontheoutcomesofneovascularagerelatedmaculardegenerationtreatedusingafliberceptarealworldstudy
AT hsiehyiting impactofretinalfluidtoleranceontheoutcomesofneovascularagerelatedmaculardegenerationtreatedusingafliberceptarealworldstudy
AT linchangping impactofretinalfluidtoleranceontheoutcomesofneovascularagerelatedmaculardegenerationtreatedusingafliberceptarealworldstudy
AT hotzyychang impactofretinalfluidtoleranceontheoutcomesofneovascularagerelatedmaculardegenerationtreatedusingafliberceptarealworldstudy
AT yangchungmay impactofretinalfluidtoleranceontheoutcomesofneovascularagerelatedmaculardegenerationtreatedusingafliberceptarealworldstudy
AT yangchanghao impactofretinalfluidtoleranceontheoutcomesofneovascularagerelatedmaculardegenerationtreatedusingafliberceptarealworldstudy